Clinical Trials · NCT03388619
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 30
- Start date
- Jan 2018
- Locations
- 1 site, United States
- Primary endpoint
- Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy)